Remove 2023 Remove Disease Remove Nuclear Medicine
article thumbnail

Road to RSNA 2023: Molecular Imaging

AuntMinnie

This is just the third year that RSNA has offered a dedicated track on nuclear medicine and molecular imaging, with eight scientific sessions covering research in prostate cancer imaging, breast cancer, cardiovascular and pulmonary imaging, and more. There will be also 30 educational courses and 14 poster sessions. 9:30 a.m. |

article thumbnail

PET reveals patient responses to new Alzheimer’s disease drug

AuntMinnie

Patients with less tau pathology on PET scans may respond better to treatment with the new Alzheimer’s disease drug donanemab, according to an October 25 news report in the journal Practical Neurology. Food and Drug Administration, with a decision expected by the end of 2023. Donanemab is currently under review for approval by the U.S.

Disease 298
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Society of Nuclear Medicine and Molecular Imaging Names Helen Nadel, MD, FRCPC, of Stanford, as President, Announces New Officers at SNMMI 2023 Annual Meeting

Imaging Technology

The Society introduced a new slate of officers, and recognized new Fellows, during its SNMMI 2023 Annual Meeting , held June 24-27 in Chicago, IL. The potential impact of nuclear medicine in the care of patients dealing with cancer, heart disease, brain disease, and other challenges is enormous,” she said. “We

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.

article thumbnail

Treatment paradigm shifting for men with prostate cancer

AuntMinnie

New imaging and treatment strategies are emerging to prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC), according to a presentation at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.

article thumbnail

Meet the Minnies 2024 finalists

AuntMinnie

His research interests include using structural and functional MRI -- particularly ultrahigh-field, 7-tesla MRI -- to map brain microstructure and develop neurosurgical treatment of brain tumors, epilepsy, and neurodegenerative and movement disorders such as Parkinson's disease, essential tremor, and dystonia. Elliot Fishman, MD.

article thumbnail

SNMMI: Y-90-FAPI-46 more effective for advanced sarcoma

AuntMinnie

An emerging radioligand therapy could be particularly effective for controlling advanced sarcoma compared to other cancers, according to research presented June 8 in a Young Investigator Award session at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Toronto. Image courtesy of SNMMI.